Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)

By sjmartinez • October 26, 2023

Neelapu SS, Chavez JC, Sehgal A, Epperla N, Ulrickson ML, Bachy E, Munshi P, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO Dr, Yakoubagha I, Khanal R, Rosenblatt JD, Korn R, Peng W, Lui C, Wullf J, Shen RR, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA. Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5). Blood. 2023 Oct 25:blood.2023021243. doi: 10.1182/blood.2023021243. Epub ahead of print. PMID: 37879047.

Tags: Hematology/Oncology, Publications

Developing remote patient monitoring infrastructure using commercially available cloud platforms

Cao M, Ramezani R, Katakwar VK, Zhang W, Boda D, Wani M, Naeim A. Developing remote patient monitoring infrastructure using commercially available cloud platforms. Front[...]

INteractive survivorship program to improve health care REsources [INSPIRE]: A study protocol testing a digital intervention with stepped care telehealth to improve outcomes for adolescent and young adult survivors

Yi JC, Ballard S, Walsh C, Friedman DN, Ganz PA, Jacobs LA, Partridge AH, Mitchell SA, Leisenring WM, Syrjala KL, Baker KS. INteractive survivorship program[...]

Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma

Bitar R, Salem R, Finn R, Greten TF, Goldberg SN, Chapiro J. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma. Radiology. 2024 Nov;313(2):e232875. doi:[...]